All data are based on the daily closing price as of March 13, 2026
m
Medy-Tox
086900.KQ
78.99 USD
-1.12
-1.40%
Overview
Last close
78.99 usd
Market cap
519.69M usd
52 week high
149.12 usd
52 week low
76.77 usd
Target price
101.32 usd
Valuation
P/E
N/A
Forward P/E
32.0513
Price/Sales
3.1996
Price/Book Value
1.6772
Enterprise Value
532.55M usd
EV/Revenue
3.2956
EV/EBITDA
38.8395
Key financials
Revenue TTM
161.60M usd
Gross Profit TTM
93.44M usd
EBITDA TTM
27.95M usd
Earnings per Share
N/A usd
Dividend
3.21 usd
Total assets
419.01M usd
Net debt
11.09M usd
About
Medy-Tox Inc. operates as a biopharmaceutical company in South Korea. It provides botulinum toxin products, including Neuronox, a lyophilized white power for injection that is used to treat foot deformities due to spasticity in pediatric cerebral palsy patients; INNOTOX, a colorless transparent liquid-filled injection that is used to temporarily improve moderate to severe glabellar wrinkles; and Coretox, a lyophilized white power for injection that is used to temporarily improve moderate to severe glabellar wrinkles. The company also offers hyaluronic acid filler products comprising Neuramis and Potenfill that are tissue recovering biomaterials. In addition, it provides various medical devices, such as ComfortDual for tissue coagulation by using high-frequency current; Neurajet Plus to assist injecting other pharmaceuticals; and Carewave for improving erectile dysfunction by using low-intensity shock wave generated from the electromagnetic method. It also exports its products to approximately 60 countries, including Japan, Brazil, and internationally. Medy-Tox Inc. was founded in 2000 and is headquartered in Cheongju, South Korea.